308 related articles for article (PubMed ID: 14604966)
21. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.
Li H; Nakashima H; Decklever TD; Nace RA; Russell SJ
Cancer Gene Ther; 2013 Aug; 20(8):478-85. PubMed ID: 23868101
[TBL] [Abstract][Full Text] [Related]
22. Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition.
Touchefeu Y; Khan AA; Borst G; Zaidi SH; McLaughlin M; Roulstone V; Mansfield D; Kyula J; Pencavel T; Karapanagiotou EM; Clayton J; Federspiel MJ; Russell SJ; Garrett M; Collins I; Harrington KJ
Radiother Oncol; 2013 Jul; 108(1):24-31. PubMed ID: 23849174
[TBL] [Abstract][Full Text] [Related]
23. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.
Myers RM; Greiner SM; Harvey ME; Griesmann G; Kuffel MJ; Buhrow SA; Reid JM; Federspiel M; Ames MM; Dingli D; Schweikart K; Welch A; Dispenzieri A; Peng KW; Russell SJ
Clin Pharmacol Ther; 2007 Dec; 82(6):700-10. PubMed ID: 17971816
[TBL] [Abstract][Full Text] [Related]
24. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
25. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.
Grünwald GK; Vetter A; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Wagner E; Göke B; Holm PS; Ogris M; Spitzweg C
J Nucl Med; 2013 Aug; 54(8):1450-7. PubMed ID: 23843567
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.
Peng KW; Donovan KA; Schneider U; Cattaneo R; Lust JA; Russell SJ
Blood; 2003 Apr; 101(7):2557-62. PubMed ID: 12433686
[TBL] [Abstract][Full Text] [Related]
28. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
Msaouel P; Opyrchal M; Dispenzieri A; Peng KW; Federspiel MJ; Russell SJ; Galanis E
Curr Cancer Drug Targets; 2018; 18(2):177-187. PubMed ID: 28228086
[TBL] [Abstract][Full Text] [Related]
29. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.
Ayala-Breton C; Suksanpaisan L; Mader EK; Russell SJ; Peng KW
Mol Ther; 2013 Oct; 21(10):1930-7. PubMed ID: 23842448
[TBL] [Abstract][Full Text] [Related]
30. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
[TBL] [Abstract][Full Text] [Related]
31. A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer.
Trujillo MA; Oneal MJ; McDonough S; Qin R; Morris JC
Cancer Gene Ther; 2012 Dec; 19(12):839-44. PubMed ID: 23037808
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
33. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
Msaouel P; Dispenzieri A; Galanis E
Curr Opin Mol Ther; 2009 Feb; 11(1):43-53. PubMed ID: 19169959
[TBL] [Abstract][Full Text] [Related]
34. Enhancing cytokine-induced killer cell therapy of multiple myeloma.
Liu C; Suksanpaisan L; Chen YW; Russell SJ; Peng KW
Exp Hematol; 2013 Jun; 41(6):508-17. PubMed ID: 23403007
[TBL] [Abstract][Full Text] [Related]
35. In vivo molecular imaging and radionuclide (131I) therapy of human nasopharyngeal carcinoma cells transfected with a lentivirus expressing sodium iodide symporter.
Shi S; Zhang M; Guo R; Miao Y; Hu J; Xi Y; Li B
PLoS One; 2015; 10(1):e0116531. PubMed ID: 25621996
[TBL] [Abstract][Full Text] [Related]
36. Mathematical modeling of cancer radiovirotherapy.
Dingli D; Cascino MD; Josić K; Russell SJ; Bajzer Z
Math Biosci; 2006 Jan; 199(1):55-78. PubMed ID: 16376950
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N; Upreti D; Zhou Y; Khan R; Miller A; Diaz RM; Rooney CM; Dispenzieri A; Peng KW; Russell SJ
Leukemia; 2020 Dec; 34(12):3310-3322. PubMed ID: 32327728
[TBL] [Abstract][Full Text] [Related]
39. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter.
Spitzweg C; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
Cancer Res; 2000 Nov; 60(22):6526-30. PubMed ID: 11103823
[TBL] [Abstract][Full Text] [Related]
40. Genetically targeted radiotherapy for multiple myeloma.
Dingli D; Diaz RM; Bergert ER; O'Connor MK; Morris JC; Russell SJ
Blood; 2003 Jul; 102(2):489-96. PubMed ID: 12649158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
